7 completed, 1 active not recruiting, 1 not yet recruiting. 5 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Not yet recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Vincentage Pharma Co., Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control VCT220 tablets, Placebo - Type 2 Diabetes Mellitus (DM) | Phase 2 | Not yet recruiting | Vincentage Pharma Co., Ltd | 120 | 2026-11-01 | 2026-10-13 |
| A Food-Effect Study of CX11 in Healthy Participants CX11 (VCT220) - Obesity & Overweight, Type 2 Diabetes | Phase 1 | Completed | Vincentage Pharma Co., Ltd | 32 | 2026-03-04 | 2026-10-13 |
| A Study of VCT220 in Participants With Hypertension and Obesity or Overweight VCT220 Tablet, VCT220 Placebo Tablet - Hypertension | Phase 2 | Active not recruiting | Vincentage Pharma Co., Ltd | 160 | 2026-03-01 | 2026-09-21 |
| A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients VCT220 - Obesity & Overweight | Phase 1 | Completed | Vincentage Pharma Co., Ltd | 16 | 2025-12-25 | 2026-03-27 |
| This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole Rifampin + VCT220, Itraconazole + VCT220 - Obesity &Amp; Overweight | Phase 1 | Completed | Vincentage Pharma Co., Ltd | 32 | 2025-07-20 | 2026-03-31 |
| A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin - Obesity &Amp; Overweight | Phase 1 | Completed | Vincentage Pharma Co., Ltd | 24 | 2025-07-01 | 2026-03-31 |
| A Pharmacokinetic Study of VCT220 in Particicants With Hepatic Injury and Normal Hepatic Function VCT220, Placebo - Obesity, Overweight | Phase 1 | Completed | Vincentage Pharma Co., Ltd | 24 | 2025-04-18 | 2025-08-14 |
| A Research Study of VCT220 in Adult Chinese Participants With Obesity VCT220, Placebo - Obesity, Overweight | Phase 3 | Completed | Vincentage Pharma Co., Ltd | 840 | 2024-12-24 | 2026-09-16 |
| A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population VCT220, Placebo - Obesity, Overweight | Phase 2 | Completed | Vincentage Pharma Co., Ltd | 250 | 2023-12-27 | 2025-07-01 |
Obesity (7) · Overweight (7) · Diabetes Mellitus, Type 2 (2) · Hypertension (1)
Digoxin (1) · Itraconazole (1) · Rifampin (1) · Rosuvastatin Calcium (1) · repaglinide (1)
China (9)